Sotera Health price target lowered to $18 from $20 at Barclays

Barclays lowered the firm’s price target on Sotera Health (SHC) to $18 from $20 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.